Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies
Identifieur interne : 002877 ( Main/Exploration ); précédent : 002876; suivant : 002878Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies
Auteurs : Jennifer G. Goldman [États-Unis] ; Christopher G. Goetz [États-Unis] ; Melanie Brandabur [États-Unis] ; Michelle Sanfilippo [États-Unis] ; Glenn T. Stebbins [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-11-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Chemotherapy, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Female, Follow-Up Studies, Hallucinations (chemically induced), Humans, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Lewy Body Disease (complications), Lewy body dementia, Male, Mental Disorders (drug therapy), Mental Disorders (etiology), Movement Disorders (drug therapy), Movement Disorders (etiology), Nervous system diseases, Parkinsonism, Psychosis, dementia with Lewy bodies, levodopa, parkinsonism, psychosis.
- MESH :
- chemical , adverse effects : Dopamine Agonists, Levodopa.
- chemical , therapeutic use : Dopamine Agonists, Levodopa.
- chemically induced : Hallucinations.
- complications : Lewy Body Disease.
- drug therapy : Mental Disorders, Movement Disorders.
- etiology : Mental Disorders, Movement Disorders.
- Aged, Female, Follow-Up Studies, Humans, Male.
Abstract
Dopaminergic treatment in dementia with Lewy bodies (DLB) requires balancing risk of worsened psychosis and potential motor benefit. We assessed the effects of increased dopaminergic medication on psychosis and motor function in DLB. We studied 19 subjects fulfilling probable DLB Consensus criteria before and after increased dopaminergic medications. Standard clinical measures included: Thought Disorder score from the Unified Parkinson's disease Rating Scale (UPDRS) Part I, total motor score (UPDRS Part III), and Hoehn–Yahr (H&Y) stage. Motor benefit defined as >10% improvement over baseline UPDRS Part III score, occurred in only one‐third of subjects. In this group, worsened hallucinations or psychosis developed in one‐third. Considering motor benefit without exacerbation of psychosis as our aim, only 4 DLB subjects (22%) achieved this goal. Our results suggest that dopaminergic medications have limited benefit in DLB because of the low likelihood of motor improvement and the risk of psychosis exacerbation. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22322
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000D85
- to stream Istex, to step Curation: 000D85
- to stream Istex, to step Checkpoint: 001433
- to stream PubMed, to step Corpus: 002002
- to stream PubMed, to step Curation: 002002
- to stream PubMed, to step Checkpoint: 002319
- to stream Ncbi, to step Merge: 002361
- to stream Ncbi, to step Curation: 002361
- to stream Ncbi, to step Checkpoint: 002361
- to stream Main, to step Merge: 003455
- to stream PascalFrancis, to step Corpus: 001039
- to stream PascalFrancis, to step Curation: 001C80
- to stream PascalFrancis, to step Checkpoint: 001275
- to stream Main, to step Merge: 003883
- to stream Main, to step Curation: 002877
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies</title><author><name sortKey="Goldman, Jennifer G" sort="Goldman, Jennifer G" uniqKey="Goldman J" first="Jennifer G." last="Goldman">Jennifer G. Goldman</name></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></author><author><name sortKey="Brandabur, Melanie" sort="Brandabur, Melanie" uniqKey="Brandabur M" first="Melanie" last="Brandabur">Melanie Brandabur</name></author><author><name sortKey="Sanfilippo, Michelle" sort="Sanfilippo, Michelle" uniqKey="Sanfilippo M" first="Michelle" last="Sanfilippo">Michelle Sanfilippo</name></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:703B26348C301260BF0038B8C7D07B12390CE0DD</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22322</idno><idno type="url">https://api.istex.fr/document/703B26348C301260BF0038B8C7D07B12390CE0DD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D85</idno><idno type="wicri:Area/Istex/Curation">000D85</idno><idno type="wicri:Area/Istex/Checkpoint">001433</idno><idno type="wicri:doubleKey">0885-3185:2008:Goldman J:effects:of:dopaminergic</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18823039</idno><idno type="wicri:Area/PubMed/Corpus">002002</idno><idno type="wicri:Area/PubMed/Curation">002002</idno><idno type="wicri:Area/PubMed/Checkpoint">002319</idno><idno type="wicri:Area/Ncbi/Merge">002361</idno><idno type="wicri:Area/Ncbi/Curation">002361</idno><idno type="wicri:Area/Ncbi/Checkpoint">002361</idno><idno type="wicri:Area/Main/Merge">003455</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0038034</idno><idno type="wicri:Area/PascalFrancis/Corpus">001039</idno><idno type="wicri:Area/PascalFrancis/Curation">001C80</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001275</idno><idno type="wicri:doubleKey">0885-3185:2008:Goldman J:effects:of:dopaminergic</idno><idno type="wicri:Area/Main/Merge">003883</idno><idno type="wicri:Area/Main/Curation">002877</idno><idno type="wicri:Area/Main/Exploration">002877</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies</title><author><name sortKey="Goldman, Jennifer G" sort="Goldman, Jennifer G" uniqKey="Goldman J" first="Jennifer G." last="Goldman">Jennifer G. Goldman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Brandabur, Melanie" sort="Brandabur, Melanie" uniqKey="Brandabur M" first="Melanie" last="Brandabur">Melanie Brandabur</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Sanfilippo, Michelle" sort="Sanfilippo, Michelle" uniqKey="Sanfilippo M" first="Michelle" last="Sanfilippo">Michelle Sanfilippo</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Alexian Brothers Neuroscience Institute, Hoffman Estates, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-11-15">2008-11-15</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="2248">2248</biblScope><biblScope unit="page" to="2250">2250</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">703B26348C301260BF0038B8C7D07B12390CE0DD</idno><idno type="DOI">10.1002/mds.22322</idno><idno type="ArticleID">MDS22322</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Chemotherapy</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Female</term><term>Follow-Up Studies</term><term>Hallucinations (chemically induced)</term><term>Humans</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Lewy Body Disease (complications)</term><term>Lewy body dementia</term><term>Male</term><term>Mental Disorders (drug therapy)</term><term>Mental Disorders (etiology)</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Nervous system diseases</term><term>Parkinsonism</term><term>Psychosis</term><term>dementia with Lewy bodies</term><term>levodopa</term><term>parkinsonism</term><term>psychosis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hallucinations</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lewy Body Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Mental Disorders</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Mental Disorders</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Chimiothérapie</term><term>Démence à corps de Lewy</term><term>Lévodopa</term><term>Parkinsonisme</term><term>Pathologie du système nerveux</term><term>Psychose</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopaminergic treatment in dementia with Lewy bodies (DLB) requires balancing risk of worsened psychosis and potential motor benefit. We assessed the effects of increased dopaminergic medication on psychosis and motor function in DLB. We studied 19 subjects fulfilling probable DLB Consensus criteria before and after increased dopaminergic medications. Standard clinical measures included: Thought Disorder score from the Unified Parkinson's disease Rating Scale (UPDRS) Part I, total motor score (UPDRS Part III), and Hoehn–Yahr (H&Y) stage. Motor benefit defined as >10% improvement over baseline UPDRS Part III score, occurred in only one‐third of subjects. In this group, worsened hallucinations or psychosis developed in one‐third. Considering motor benefit without exacerbation of psychosis as our aim, only 4 DLB subjects (22%) achieved this goal. Our results suggest that dopaminergic medications have limited benefit in DLB because of the low likelihood of motor improvement and the risk of psychosis exacerbation. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Illinois</li></region></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Goldman, Jennifer G" sort="Goldman, Jennifer G" uniqKey="Goldman J" first="Jennifer G." last="Goldman">Jennifer G. Goldman</name></region><name sortKey="Brandabur, Melanie" sort="Brandabur, Melanie" uniqKey="Brandabur M" first="Melanie" last="Brandabur">Melanie Brandabur</name><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><name sortKey="Sanfilippo, Michelle" sort="Sanfilippo, Michelle" uniqKey="Sanfilippo M" first="Michelle" last="Sanfilippo">Michelle Sanfilippo</name><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002877 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002877 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:703B26348C301260BF0038B8C7D07B12390CE0DD
|texte= Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies
}}
| This area was generated with Dilib version V0.6.23. |  |